Anna L Olsen

Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors

Ruth Plummer, Christopher J. Jones, Mark R. Middleton et al. · Clinical Cancer Research · 2008 · 384 citations · Full text

Medicine, Oncology, Pharmacology +15

PARP1 and PARP2 stabilise replication forks at base excision repair intermediates through Fbh1-dependent Rad51 regulation

George E. Ronson, Ann Liza Piberger, Martin R. Higgs et al. · Nature Communications · 2018 · 217 citations · Full text

Life Sciences, Genetics, Molecular Biology +17

LARD: A new lymphoid-specific death domain containing receptor regulated by alternative pre-mRNA splicing

Gavin Screaton, Xiao-Ning Xu, Anna L Olsen et al. · Proceedings of the National Academy of Sciences · 1997 · 210 citations

Life Sciences, Immunology, Molecular Biology +17

XPF-ERCC1 Participates in the Fanconi Anemia Pathway of Cross-Link Repair

Nikhil R. Bhagwat, Anna L Olsen, Anderson T. Wang et al. · Molecular and Cellular Biology · 2009 · 140 citations · Full text

Life Sciences, Genetics, Molecular Biology +17

Temozolomide Pharmacodynamics in Patients with Metastatic Melanoma: DNA Damage and Activity of Repair Enzymes <i>O</i>6-Alkylguanine Alkyltransferase and Poly(ADP-Ribose) Polymerase-1

Elizabeth Ruth Plummer, Mark R. Middleton, Christopher J. Jones et al. · Clinical Cancer Research · 2005 · 103 citations

Medicine, Oncology, Cancer Pharmacology +16